UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~ 29July 7, 2026

PRAXIS PRECISION MEDICINES, INC.

(Exact name of registrant as specified in its charter)

Delaware	~~001-39620~~	~~47-5195942~~	001-39620	47-5195942
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or other jurisdictionof incorporation)			(CommissionFile Number)	(I.R.S. EmployerIdentification No.)

Praxis Precision Medicines, Inc.

99 High Street, 30th Floor

Boston, Massachusetts 02110

(Address of principal executive offices, including zip code)

(617) 300-8460

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

~~Trade Symbol(s)~~

~~Name of each exchange on which registered~~

TradeSymbol(s)

Name of each exchangeon which registered

Common Stock, $0.0001 par value per share

~~PRAX~~

~~The Nasdaq Global Select Market~~

PRAX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨ ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ☐

Item 48.01. Other ~~Changes in Registrant's Certifying Accountant~~Events.

~~Dismissal~~On July 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the Company entered into a research collaboration and license agreement (the “Agreement”) with Remagine Labs, Inc., a developer of ~~Independent~~electronically ~~Registered~~controlled ~~Public~~transdermal ~~Accounting~~drug ~~Firm~~delivery systems (“Remagine”), to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide for essential tremor. Under the Agreement, the Company and Remagine will collaborate to apply Remagine’s proprietary platform, designed for precise, multi-day active transdermal dosing, to ulixacaltamide, complementing the Company’s lead oral program. A transdermal option is intended to broaden the population ulixacaltamide can reach, while strengthening ulixacaltamide’s competitive positioning and extending the long-term value of the franchise. The Company has also made an equity investment in Remagine, underscoring the companies’ shared commitment to quickly advancing the program.

OnForward-Looking June 29, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of Praxis Precision Medicines, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm, effective as of that date.Statements

~~The~~This ~~reports~~Current Report on Form 8-K contains forward-looking statements within the meaning of EYthe onPrivate Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the Company'’s ~~financial~~strategic collaboration with Remagine and the development and potential market opportunity of ulixacaltamide. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, including, without limitation, uncertainties inherent in clinical trials and other risks as described in the Company’s Annual Report on Form 10-K for the ~~fiscal years~~year ended December 31, 2025 and ~~December~~other ~~31,~~filings ~~2024~~with ~~did~~the ~~not~~Securities ~~contain~~and anExchange ~~adverse~~Commission. ~~opinion~~These orstatements aare ~~disclaimer~~based only on facts currently known by the Company and speak only as of ~~opinion~~the date of this Current Report on Form 8-K. As a result, ~~and~~you ~~were~~are cautioned not ~~qualified~~ to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or ~~modified~~revise any forward-looking statement, whether as toa ~~uncertainty~~result of new information, ~~audit~~future ~~scope~~developments or ~~accounting principles~~otherwise.

~~During~~SIGNATURE the fiscal years ended December 31, 2025 and December 31, 2024 and through June 29, 2026, there were no: (i) disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with EY on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused it to make reference to the subject matter of the disagreements in connection with its reports; or (ii) reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).

~~The~~Pursuant ~~Company~~to ~~has~~the ~~provided~~requirements ~~EY with a copy~~ of the ~~disclosures it is making in this Current Report on Form 8-K and has requested that EY furnish a letter addressed to the~~ Securities ~~and~~ Exchange ~~Commission~~Act ~~stating whether~~of it1934, ~~agrees with~~ the ~~statements~~registrant ~~made~~has byduly ~~the~~caused ~~Company~~this inreport ~~this~~to ~~Current~~be ~~Report~~signed on ~~Form~~its ~~8-K~~behalf ~~and,~~by ~~if not, stating~~ the ~~respects~~undersigned inhereunto ~~which it~~duly ~~does not agree~~authorized. ~~A copy of the letter from EY is attached as Exhibit 16.1 to this Current Report on Form 8-K.~~

Engagement of New Independent Registered Public Accounting Firm


	PRAXIS PRECISION MEDICINES, INC.

Date: July 7, 2026	By:	/s/ Marcio Souza
		Marcio Souza
		Chief Executive Officer

On June 29, 2026, the Audit Committee approved the engagement of KPMG LLP ("KPMG") as the Company's new independent registered public accounting firm, effective as of that date.

During the fiscal years ended December 31, 2025 and December 31, 2024 and through June 29, 2026, neither the Company nor anyone on its behalf has consulted with KPMG regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company by KPMG that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

16.1 Letter from Ernst & Young LLP to the Securities and Exchange Commission, dated July 2, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PRAXIS PRECISION MEDICINES, INC.
Date: July 2, 2026	By:	/s/ Marcio Souza
		Marcio Souza
		Chief Executive Officer

Filing Compare · Praxis Precision Medicines, Inc.